S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
NASDAQ:DYAX

Dyax (DYAX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$38.41
$38.41
50-Day Range
N/A
52-Week Range
$14.06
$38.56
Volume
N/A
Average Volume
5.25 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
DYAX stock logo

About Dyax Stock (NASDAQ:DYAX)

Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.

DYAX Stock News Headlines

Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
S-1: NutriBand Inc.
No more deaths recorded in Bristol
See More Headlines
Receive DYAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyax and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/28/2015
Today
4/20/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:DYAX
CUSIP
26746E10
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

DYAX Stock Analysis - Frequently Asked Questions

How were Dyax's earnings last quarter?

Dyax Corp (NASDAQ:DYAX) announced its quarterly earnings data on Wednesday, October, 28th. The biopharmaceutical company reported ($0.08) EPS for the quarter, meeting analysts' consensus estimates of ($0.08). The biopharmaceutical company earned $24.70 million during the quarter, compared to analyst estimates of $24.96 million. Dyax's revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.01) EPS.

What other stocks do shareholders of Dyax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dyax investors own include (KRFT) (KRFT), ASML (ASML), Bank of Nova Scotia (BNS), DOW (DOW), Dover Motorsports (DVD), Novavax (NVAX), Prudential (PRU), Standard Chartered (STAN), Anthera Pharmaceuticals (ANTH) and Ariad Pharmaceuticals (ARIA).

This page (NASDAQ:DYAX) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners